Diffusion Pharmaceuticals Inc logo

DFFN - Diffusion Pharmaceuticals Inc Share Price

$1.24 0.1  6.5%

Last Trade - 3:46pm

Sector
Healthcare
Size
Small Cap
Market Cap £54.1m
Enterprise Value £38.1m
Revenue £n/a
Position in Universe 5035th / 6626
Bullish
Bearish
Unlock DFFN Revenue
Momentum
Relative Strength (%)
1m +56.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Diffusion Pharmaceuticals Inc revenues was not reported.Net loss applicable to common stockholders increased 50% to$12.1M. Higher net loss reflects Research and development -Balancing val increase of 35% to $6.6M (expense), Generaland administrative - Balancing increase of 43% to $4.6M(expense), Stock-based Compensation in R&D increase from$41K to $208K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DFFN Revenue Unlock DFFN Revenue

Net Income

DFFN Net Income Unlock DFFN Revenue

Normalised EPS

DFFN Normalised EPS Unlock DFFN Revenue

PE Ratio Range

DFFN PE Ratio Range Unlock DFFN Revenue

Dividend Yield Range

DFFN Dividend Yield Range Unlock DFFN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DFFN EPS Forecasts Unlock DFFN Revenue
Profile Summary

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 17, 2015
Public Since November 9, 2016
No. of Shareholders: 480
No. of Employees: 10
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 64,015,441
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DFFN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DFFN
Upcoming Events for DFFN
Frequently Asked Questions for Diffusion Pharmaceuticals Inc
What is the Diffusion Pharmaceuticals Inc share price?

As of 3:46pm, shares in Diffusion Pharmaceuticals Inc are trading at $1.24, giving the company a market capitalisation of £54.1m. This share price information is delayed by 15 minutes.

How has the Diffusion Pharmaceuticals Inc share price performed this year?

Shares in Diffusion Pharmaceuticals Inc are currently trading at $1.24 and the price has moved by 0.138k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Diffusion Pharmaceuticals Inc price has moved by 0.105k% over the past year.

What are the analyst and broker recommendations for Diffusion Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Diffusion Pharmaceuticals Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Diffusion Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Diffusion Pharmaceuticals Inc next release its financial results?

Diffusion Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Diffusion Pharmaceuticals Inc dividend yield?

Diffusion Pharmaceuticals Inc does not currently pay a dividend.

Does Diffusion Pharmaceuticals Inc pay a dividend?

Diffusion Pharmaceuticals Inc does not currently pay a dividend.

When does Diffusion Pharmaceuticals Inc next pay dividends?

Diffusion Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Diffusion Pharmaceuticals Inc shares?

To buy shares in Diffusion Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Diffusion Pharmaceuticals Inc?

Shares in Diffusion Pharmaceuticals Inc are currently trading at $1.24, giving the company a market capitalisation of £54.1m.

Where are Diffusion Pharmaceuticals Inc shares listed? Where are Diffusion Pharmaceuticals Inc shares listed?

Here are the trading details for Diffusion Pharmaceuticals Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: DFFN
What kind of share is Diffusion Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Diffusion Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Diffusion Pharmaceuticals Inc share price forecast 2021?

Shares in Diffusion Pharmaceuticals Inc are currently priced at $1.24. At that level they are trading at 0.137% discount to the analyst consensus target price of 0.00.

Analysts covering Diffusion Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.28 for the next financial year.

How can I tell whether the Diffusion Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diffusion Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -26.09%. At the current price of $1.24, shares in Diffusion Pharmaceuticals Inc are trading at 30.23% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Diffusion Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Diffusion Pharmaceuticals Inc.

Who are the key directors of Diffusion Pharmaceuticals Inc?

We were unable to find the directors for Diffusion Pharmaceuticals Inc.

Who are the major shareholders of Diffusion Pharmaceuticals Inc?

Here are the top five shareholders of Diffusion Pharmaceuticals Inc based on the size of their shareholding:

Renaissance Technologies LLC Hedge Fund
Percentage owned: 4.67% (2.99m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 2.74% (1.76m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.3% (830k shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 0.56% (358k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 0.55% (352k shares)
Similar to DFFN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.